Precision Genomics & Microbiome Solutions for Hospitals
Geval partners with hospitals, diagnostic centers, and academic institutions to integrate advanced genomic and microbiome analytics into existing clinical workflows. Our services are designed to support early risk identification, population screening, and personalized prevention, while remaining cost-effective and scalable using our GeneReveal™ Platform, our proprietary analytics platform, rated at the highest level by the European Molecular Genetics Quality Network (EMQN).
Note for individuals and non-clinical organizations:
Geval does not provide direct-to-consumer testing. Please consult your healthcare provider or hospital to learn whether Geval-powered testing options are available to you.
Polygenic Risk Score (PRS)–Based Risk Assessment
For Hospitals & Health Systems:
Geval provides whole-genome–based Polygenic Risk Scores (PRS) that quantify inherited risk for complex diseases by aggregating thousands to millions of genetic variants.
Clinical Applications
- Breast cancer risk stratification
- Prostate cancer risk assessment
- Cardiovascular disease risk prediction
- Type 2 diabetes and metabolic disease risk
Key Benefits
- Earlier identification of high-risk individuals
- Supports transition from age-based to risk-based screening
- Population-calibrated models for improved accuracy
- Complements existing diagnostic tools
PRS services are delivered as clinical decision-support reports designed for physician interpretation and integration into hospital workflows.
Low-Coverage Whole-Genome Sequencing (LC-WGS)
For Scalable Clinical & Population Screening:
Geval uses low-coverage whole-genome sequencing combined with advanced imputation to deliver genome-wide insights at a fraction of the cost of traditional high-coverage sequencing.
Use Cases
- First-tier genomic screening
- Large-scale preventive programs
- Cost-sensitive hospital deployments
Advantages
- Cost-effective without compromising clinical relevance
- Suitable for large patient cohorts
- Enables PRS and genome-wide risk analysis
Long-Read Sequencing for Structural Variant Detection
For Advanced Clinical Investigations:
Long-read sequencing enables detection of structural variants and complex genomic regions that may be missed by standard short-read methods.
Applications
- Complex cancer genetics
- Rare or difficult-to-detect variants
- Complementary analysis alongside LC-WGS
Hospitals can deploy long-read sequencing as a targeted add-on service based on clinical needs.
Population-Specific Genomic Risk Models
Improving Accuracy Across Diverse Populations:
Many global genomic models are optimized for European ancestry populations. Geval develops population-specific reference panels and PRS models to improve predictive accuracy for diverse patient groups.
Benefits
- Reduced bias in genetic risk prediction
- Improved clinical relevance
- Supports equity in precision medicine
This service is particularly valuable for hospitals serving multi-ethnic or underrepresented populations.
Gut Microbiome–Based Diagnostics
For Colorectal Cancer & Metabolic Disorders:
Geval offers microbiome diagnostics based on stool-derived microbial DNA sequencing, supported by AI-driven analytics.
Clinical Applications
- Colorectal cancer risk assessment
- Metabolic disorder insights
- Integrated genomics + microbiome analysis
Advantages
- Non-invasive diagnostic support
- Population-specific microbial signatures
- Complements existing screening tools
Integrated Genomics & Microbiome Analytics
AI-Powered Clinical Insight
All Geval services are supported by GeneReveal™, our proprietary analytics platform, rated at the highest level by the European Molecular Genetics Quality Network (EMQN).
Platform Capabilities
- Integrated genomic and microbiome analysis
- Clinician-ready reports
- Actionable, interpretable insights
- Scalable deployment for hospitals
For Individuals & Non-Clinical Organizations
Geval services are not offered directly to individuals.
If you are:
- A patient
- An employer
- An insurance provider
- A wellness organization
Please consult your hospital, physician, or healthcare provider to learn whether Geval-powered genomic or microbiome testing is available through their clinical programs.
Take the Next Step: For Hospitals & Institutions
Partner with Geval to integrate cost-effective, population-specific precision medicine solutions into your clinical practice. Contact us to explore collaboration opportunities, pilot programs, or clinical deployment options.
